September 4, 2015 / 3:46 AM / 2 years ago

India's Cipla says to buy two U.S. generics firms for $550 mln

MUMBAI, Sept 4 (Reuters) - Cipla Ltd, India's fourth-largest drugmaker by sales, said on Friday it has agreed to buy two generics businesses in the United States in an all-cash deal worth $550 million to get access to a wide range of products.

The companies to be acquired, InvaGen Pharmaceuticals Inc and Exelan Pharmaceuticals Inc, had combined sales of $225 million in the last twelve months to June 2015, Cipla said in a statement. (Reporting by Zeba Siddiqui in Mumbai)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below